Elbona solution for injection. 200mg / ml, 2ml # 6

• Primary and secondary osteoarthritis;

• spondyloarthrosis.

ElbonaЃ is administered intramuscularly! The drug is not intended for intravenous administration.

Before the introduction, you should mix the solvent (solution B) with the drug solution (solution A) in one syringe. The prepared solution is injected intramuscularly in 3 ml (2 ml of solution A + 1 ml of solution B) 3 times a week for 4-6 weeks

Solution for intramuscular injection (solution A) colorless or light yellow, transparent; the applied solvent (solution B) - colorless, transparent; the prepared solution (solution A + solution B) is light yellow, transparent.

1 ml 1 amp.

glucosamine sulfate sodium chloride 201.25 mg 502.5 mg,

which corresponds to the content of glucosamine sulfate 200 mg 400 mg

sodium chloride 51.25 mg 102.5 mg

Excipients: trometamol (tromethamine) - up to pH 2.0-3.0, lidocaine hydrochloride - 10 mg, water d / i - up to 2 ml.

• Phenylketonuria;

• individual hypersensitivity to glucosamine, lidocaine hydrochloride and other components of the drug.

Due to the presence of lidocaine in the composition of the drug:

• cardiac conduction disorders;

• acute heart failure;

• history of epileptiform seizures;

• severe impairment of liver and kidney function;

• pregnancy;

• lactation period;

• children under 12 years of age.

The drug should be prescribed with caution to patients with chronic heart failure, arterial hypotension, bronchial asthma, diabetes mellitus, as well as with intolerance to seafood.

pharmachologic effect

A drug that stimulates the process of cartilage tissue repair. Glucosamine sulfate has anti-inflammatory and analgesic effects, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid; promotes sulfur fixation during the synthesis of chondroitinsulfuric acid, inhibits the development of degenerative processes in the joints, restores their function.

Glucosamine helps to prevent the destruction of cartilage, stimulates the restoration of cartilage tissue. Improves joint mobility, reduces the need for NSAIDs.

Side effect

From the digestive system: in some cases - flatulence, diarrhea, constipation; due to the content of lidocaine in the preparation - nausea, vomiting.

Allergic reactions: in some cases - urticaria, itching; due to the content of lidocaine in the preparation - anaphylactic reactions.

From the side of the central nervous system: due to the content of lidocaine in the preparation - drowsiness, diplopia, headache, dizziness, numbness of the tongue and oral mucosa, tremor, euphoria, disorientation.

From the side of the cardiovascular system: due to the content of lidocaine in the drug - a violation of cardiac conduction.

Application during pregnancy and lactation

The use of ElbonaЃ during pregnancy and lactation is contraindicated.

Application for violations of liver function

Contraindication: severe liver dysfunction.

Application for impaired renal function

Contraindication: severe renal dysfunction.

Application in children

Contraindicated: children under 12 years of age.

special instructions

With intolerance to seafood (shrimp, shellfish), the likelihood of developing allergic reactions increases with the use of Elbona.

Overdose

Overdose cases were not noted.

Drug interactions

Compatible with NSAIDs, paracetamol and GCS.

Cimetidine and propranolol reduce the hepatic clearance of lidocaine (a decrease in metabolism due to inhibition of microsomal oxidation and a decrease in hepatic blood flow) and increase the risk of toxic effects.

When administered with aymalin, phenytoin, verapamil, quinidine, amiodarone, the negative inotropic effect may be enhanced.

Co-administration with beta-blockers increases the risk of developing bradycardia.

When administered together, the cardiotonic effect of cardiac glycosides is weakened.

With simultaneous use with muscle relaxants, it is possible to enhance their action.

Procainamide, when used simultaneously with lidocaine, increases the risk of developing arousal of the central nervous system, hallucinations.

With the simultaneous appointment of hypnotics and sedatives, it is possible to enhance their inhibitory effect on the central nervous system.

With the on / in the introduction of hexobarbital or sodium thiopental against the background of the action of lidocaine, respiratory depression is possible.

Lidocaine potentiates the effects of MAO inhibitors.

With simultaneous use with polymyxin B, it is possible to increase the inhibitory effect on neuromuscular transmission, therefore, in this case, it is necessary to monitor the patient's respiratory function.

A decrease in the effectiveness of hypoglycemic drugs, doxorubicin, teniposide, etoposide is possible.